Kodiak Sciences stock heads into AAO data on October 9

Published on 10/08/2026 at 07:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Kodiak Sciences stock closed at USD 91.08 on October 7, 2026, down 1.36 percent as AAO 2026 approaches. Q2 loss widened to USD 65.6 million from USD 54.3 million.

KOD, US50015M1099, Illustration mit AI erstellt.

Kodiak Sciences (ISIN US50015M1099) closed at USD 91.08 on Nasdaq on October 7, 2026, down 1.36 percent from USD 92.34. The company is heading into a major clinical-data event, with three late-stage programs scheduled for presentations at AAO 2026.

AAO brings three data events

According to PR Newswire on October 7, 2026, Kodiak will present data from Zenkuda, tabirafusp-ted and KSI-101 at the American Academy of Ophthalmology meeting. The program includes the first scientific presentation of Phase 3 DAYBREAK results in wet age-related macular degeneration, plus Phase 3 GLOW2 data in diabetic retinopathy and Phase 1b APEX data in macular edema secondary to inflammation.

The DAYBREAK presentation follows topline results announced on September 28, 2026. PR Newswire reports that both investigational treatments met their primary endpoint and delivered non-inferior vision gains versus aflibercept at Year 1. That comparison gives the upcoming scientific presentation a measurable benchmark rather than a preliminary pipeline narrative.

Quarterly loss reaches USD 65.6 million

For the quarter ended June 30, 2026, Kodiak reported a net loss of USD 65.6 million, or USD 1.05 per diluted share, compared with a USD 54.3 million loss and USD 1.03 per share in the prior-year quarter. Trivano reported the figures from the company release dated August 13, 2026.

Cash and cash equivalents stood at USD 125.9 million at the end of Q2 2026, while operating cash flow was negative USD 46.238 million in the quarter. The financial profile therefore keeps clinical execution and funding discipline central to the investment case as Kodiak advances three late-stage programs.

Consensus target sits above the stock

According to MarketBeat on October 4, 2026, eight analysts comprised the consensus: six Buy ratings, one Hold and one Sell. The consensus label was Moderate Buy, with an average target of USD 100.43, which lies 10.3 percent above the October 7 price of USD 91.08.

MarketBeat also identified regulatory and execution risks alongside the potential value of the Phase 3 pipeline. That balance matters because the company remains precommercial, while the upcoming presentations may sharpen expectations for Zenkuda, tabirafusp-ted and KSI-101.

Stock remains below its yearly high

At USD 91.08 on October 7, 2026, Kodiak Sciences was 12.4 percent below its 52-week high of USD 104.00 and 732.4 percent above its 52-week low of USD 10.94. Market capitalization was USD 5.7 billion and regular-session volume was 1,304,867 shares.